July 16, 2024
Life Sciences | Tea Leaves
  • A recent report indicates that while shortages of chemotherapy drugs like cisplatin and carboplatin have eased in the United States, concerns persist among major cancer centers regarding ongoing supply issues. According to a survey released by the National Comprehensive Cancer Network, 89 percent of 28 large cancer centers across the country reported shortages of at least one drug essential for cancer treatment or managing its side effects last month. This figure remains largely unchanged from the previous year, indicating a persistent challenge in drug availability. Specifically highlighted in the survey were shortages of drugs such as vinblastine, used in treating Hodgkin’s lymphoma and other cancers, with 57 percent of centers reporting scarcity. Other critical medications like etoposide and topotecan were also noted to be in short supply, reflecting broader challenges in maintaining consistent access to essential cancer therapies in the U.S. (Article here)